News

NTM Info & Research Welcomes Attorney and Rare Disease Advocate, Candace Lerman to Board of Directors NTM Info & Research (NTMir) is pleased to announce the appointment of Candace Lerman, Esq. to the Board of Directors. Ms. Lerman is an attorney, consultant, and...

NTM Info & Research Awards Grant to Oregon Health & Science University Study Will Assess Efficacy of Hypertonic Saline in Treatment of Pulmonary NTM Disease CORAL GABLES, FL, November 24, 2020 – NTM Info & Research (NTMir), the national nonprofit organization...

NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg...

Dear Friends of NTM Info & Research, It is with a mixture of gratitude and sadness that I announce the retirement of Philip Leitman as President of NTM Info & Research. Philip, who co-founded NTMir with his late wife, Fern, will continue as President...

The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...

On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM)...

Every day, NTM Info & Research’s commitment to finding therapies serves as hope for the NTM community. We are constantly looking for ways to boost our financial support of research to achieve better treatments and, eventually, a cure. Until that cure is found,...

ARIKAYCE® is currently the only FDA approved drug designed specifically for NTM (MAC) and now available through prescription from your physician for treatment of refractory MAC lung infection in adult patients. This medication is only available through select...

Our continuing education-accredited conference is a groundbreaking opportunity for health care providers, researchers, patients, families, and caregivers to learn about the latest advances in research, treatment, and care from leaders in the field of nontuberculous...

The Food and Drug Administration is convening a public workshop titled "Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis" on Wednesday, June 27th from 8:30pm to 4:30pm ET. The purpose of this workshop is to...